Study Evaluating Management of Patients With Moderate and Severe Psoriasis

Psoriasis Clinical Trial

Official title:

Management of Patients With Moderate and Severe Psoriasis Under Treatment With Topical and/or Systemic Drugs

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00894777
• Other study ID #: 0881A6-4577
• Status: Completed
• Phase: N/A
• First received: May 6, 2009
• Last updated: November 19, 2010
• Start date: March 2009
• Est. completion date: November 2009

Study information

• Verified date: November 2010
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Observational

Clinical Trial Summary

This is an observational, naturalistic, multicenter, retrospective study to describe the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs in usual clinical practice in Spain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 469
• Est. completion date: November 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

·Over 18 years of age.·Diagnosed with moderate or severe psoriasis.·Initiated treatment with topical and/or systemic treatment between two and five years before enrollment in the study. ·Has a clinical record at the dermatologist office.

Main Exclusion Criteria:

·Currently participating in a clinical study. ·Clinical record lacks minimum data required for observational analysis.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Psoriasis

Intervention

Other:
• Clinical record review

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Descriptive analysis of the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs including sequence, doses and duration of treatment.		4 months	No
Secondary	Comparison of therapeutic management depending on patients' disease severity, using absolute and relative frequencies for qualitative variables and centralization and dispersion measures (mean, SD, median, minimum, maximum..) for quantitative variables.		4 months	No